uniQure reports FY17 results
- Co reports FY17 EPS of ($2.94) versus ($2.40) Capital IQ consensus; revs $13.1 mln versus $10.6 mln Capital IQ consensus versus $25.1 mln in 2016.
- Upcoming Anticipated Milestones
- Initiate dosing of patients in the dose confirmation study of AMT-061, data from which will be available by the end of 2018
- Initiate patient enrollment in the lead-in phase of the pivotal study of AMT-061 in the third quarter of 2018